We therefore surmised that a strategy seeking to design a molecule capable of releasing an aniline mustard (CBL-A, Scheme 1) and a MEK inhibitor in the mildly acidic milieu of the tumor microenvironment could lead to molecules capable of inducing strong potency against refractory tumor. This evidence concerns the gene MAP2K7 and neoplasm.